Submission of copy of post buyback public advertisement pertaining to buyback of shares of the Company.
AUROPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Aurobindo Pharma Ltd has completed its share buyback program. The company bought back 54,23,726 equity shares (almost the full 54,23,728 target) at ₹1,475 per share, utilizing ₹799.99 crore of the ₹800 crore authorized. The tender offer was open from April 13 to April 29, 2026, with settlement completed on May 7, 2026. The buyback attracted 26,568 valid bids for 2,904.13 lakh equity shares, which is approximately 5.43 times the maximum shares proposed to be bought back, indicating very high oversubscription. The cancellation of accepted shares will be completed by May 16, 2026.
Shareholders who participated received only about 1.87% of their tendered shares due to heavy oversubscription. The buyback represents 3.93% of total paid-up equity capital, which will reduce the company's share count and potentially support the stock price.